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ABSTRACT
Tamoxifen is an estrogen receptor antagonist used in the treat-
ment of breast cancer. It is a prodrug that is converted by several
cytochrome P450 enzymes to a primary metabolite, N-desmethylta-
moxifen (NDT), which is then further modified by CYP2D6 to a
pharmacologically potent secondary metabolite, 4-hydroxy-N-
desmethyltamoxifen (endoxifen). Antidepressants (ADs), which are
often coprescribed to patients receiving tamoxifen, are also metab-
olized by CYP2D6 and evidence suggests that a drug–drug in-
teraction between these agents adversely affects the outcome of
tamoxifen therapy by inhibiting endoxifen formation. We evaluated
this potentially important drug–drug interaction in vivo in mice
humanized for CYP2D6 (hCYP2D6). The rate of conversion of NDT
to endoxifen by hCYP2D6 mouse liver microsomes (MLMs) in vitro
was similar to that of the most active members of a panel of
13 individual human liver microsomes. Coincubation with quinidine,
a CYP2D6 inhibitor, ablated endoxifen generation by hCYP2D6
MLMs. The NDT-hydroxylation activity of wild-type MLMs was 7.4
times higher than that of hCYP2D6, whereas MLMs from Cyp2d
knockout animals were inactive. Hydroxylation of NDT correlated
with that of bufuralol, a CYP2D6 probe substrate, in the human liver
microsome panel. In vitro, ADs of the selective serotonin reuptake
inhibitor class were, by an order of magnitude, more potent inhibitors
of NDT hydroxylation by hCYP2D6 MLMs than were compounds of
the tricyclic class. At a clinically relevant dose, paroxetine pretreat-
ment inhibited the generation of endoxifen from NDT in hCYP2D6
mice in vivo. These data demonstrate the potential of ADs to af-
fect endoxifen generation and, thereby, the outcome of tamoxifen
therapy.
Introduction
Although tamoxifen has been approved for clinical use for over 40 years,
only recently has it been identified as a potential prodrug. Two hydroxylated
metabolites in particular, endoxifen and 4-hydroxytamoxifen (4-HT), have
been shown to be up to 100 times more potent estrogen receptor (ER)
antagonists than the parent compound (Johnson et al., 2004) and are
therefore likely to contribute to target inhibition and, thereby, the outcome
of therapy (Fig. 1). Because endoxifen is several times more abundant in
systemic blood samples than 4-HT, it is generally considered the more
important of these metabolites (Stearns et al., 2003; Madlensky et al.,
2011). Crucially, the rate-limiting step in the conversion of tamoxifen to
endoxifen is catalyzed by the highly polymorphic enzyme, CYP2D6
(Desta et al., 2004). Phenotypic status with regard to this enzyme
profoundly influences the circulating level of endoxifen at steady state
(Stearns et al., 2003; Mürdter et al., 2011). The clinical significance of
these observations has been scrutinized intensely, with large numbers of
retrospective studies finding both for and against an effect on therapeutic
outcome. Perhaps most notably, a meta-analysis by the International
Tamoxifen Pharmacogenomics Consortium found, when strict inclusion
criteria were applied, a clear association of CYP2D6 poor-metabolizer
status with lower rates of invasive disease-free survival on tamoxifen
therapy (Province et al., 2014).
In addition to the pharmacogenetic variability in CYP2D6 activity,
this enzyme is also the focal point for a number of clinically significant
drug–drug interactions. Between 10% and 25% of women with breast
cancer experience depression (Fann et al., 2008), whereas as many as
70%–80% experience hot flashes (hot flushes; Day et al., 1999). In both
instances, antidepressants (ADs) may be prescribed, many of which are
both substrates for and inhibitors of CYP2D6. Available clinical data
indicate a 45%–58% decrease in plasma levels of endoxifen in
individuals taking CYP2D6 inhibitors (Stearns et al., 2003; Jin et al.,
2005; Borges et al., 2006). Two of the most commonly used ADs, the
selective serotonin reuptake inhibitors (SSRIs) paroxetine and fluoxe-
tine, are classed as strong inhibitors of CYP2D6 (http://www.fda.
gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/
DrugInteractionsLabeling/ucm093664.htm#cypEnzymes) and these
have an even greater bearing on the amount of circulating endoxifen,
particularly in individuals carrying allelic variants of CYP2D6 that
confer the extensive metabolizer phenotype, with decreases of 64%–71%
(Stearns et al., 2003; Borges et al., 2006). In a retrospective population-
based cohort study of 2430 individuals who received at least one
antidepressant during tamoxifen therapy, paroxetine was found to be the
only comedication associated with an increased risk of death from breast
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cancer (Kelly et al., 2010); however, this remains a contentious finding,
because other studies have yielded conflicting results (Lehmann et al.,
2004; Chubak et al., 2008; Ahern et al., 2009; Dezentjé et al., 2010; Lash
et al., 2010).
Here, our aim was to use a CYP2D6-humanized (hCYP2D6) mouse
model to study tamoxifen metabolism, with a particular focus on
whether an in vivo interaction of tamoxifen and its metabolites with ADs
could be demonstrated.
Materials and Methods
Chemicals and Reagents. High/low cytochrome P450 (P450) activity human
liver microsome (HLM) preparations from individual donors were purchased
from BD Gentest (San Jose, CA). Pooled HLMs (150 donors) were purchased
fromThermo Fisher Scientific (Waltham,MA). Endoxifen and tamoxifen-d5 were
obtained fromToronto ResearchChemicals (Toronto, ON, Canada). NADPHwas
purchased from Melford Laboratories (Ipswich, UK). All other chemicals were
purchased from Sigma-Aldrich (Poole, UK).
Animal Lines and Husbandry. The generation and characterization of
Cyp2d-knockout (Cyp2dKO) and hCYP2D6 mice was described previously
(Scheer et al., 2012). Briefly, all nine functional murineCyp2d genes were deleted
to produce the Cyp2dKO line, and the hCYP2D6 line was generated by a targeted
insertion of an expression cassette containing 9 kb of the CYP2D6 promoter,
along with all exons, introns, and 59 and 39 untranslated regions, into the murine
Cyp2d locus. These animals were obtained from Taconic (Cologne, Germany)
and were maintained by regular outcrossing to C57/BL6N, and they were
backcrossed on the same genetic background for at least six generations.
C57BL/6N mice were used as wild-type controls. Mice were housed on sawdust
in solid-bottom, polypropylene cages and were provided an RM1 pelleted diet
(Special Diet Services Ltd., Essex, UK) and drinking water ad libitum before and
throughout the studies. The temperature was maintained within the range of 19–
23C, and the relative humidity was within the range of 40%–70%. A 12-hour
light/dark cycle was maintained. All animal procedures were carried out on 8- to
12-week old femalemice under the auspices of the Animal (Scientific Procedures)
Act of 1986, as amended by European Union Directive 2010/63/EU, and after
local ethical review.
Subcellular Fractionation. Livers were excised and snap-frozen in liquid
nitrogen for storage at280C until processing. These were thawed by the addition
of three volumes of KCl buffer [1.15% (w/v) potassium chloride, 10 mM
potassium phosphate, pH 7.4] and homogenized by a rotor-stator. Debris was
pelleted by centrifugation (11,000g at 4C for 15 minutes) and the supernatant
was withdrawn for ultracentrifugation (100,000g at 4C for 60 minutes). After
ultracentrifugation, the pellet (microsomal fraction) was resuspended in KCl
buffer containing 0.25 M sucrose. Protein content was quantified by the Bradford
assay (Bio-Rad, Hemel Hempstead, UK).
In Vitro Studies. All in vitro analyses were carried out in 100 mM potassium
phosphate buffer, pH 7.4, containing 3.3 mMMgCl2, with agitation at 400 rpm at
37C on a thermoshaker. All samples were handled in amber tubes under
conditions of subdued light for the duration of the procedure. Incubations were
initiated by the addition of NADPH to a final concentration of 1 mM and were
terminated by transferring an aliquot of the reaction mixture, typically 50 ml, to
two volumes of ice-cold acetonitrile containing internal standard (tamoxifen-d5 at
0.2 mg/ml), followed by vortexing (5 seconds) and incubation on ice. Assays to
determine the apparent kinetic parameters of endoxifen formation in hCYP2D6
mouse liver microsomes (MLMs) were performed in triplicate under conditions
of linearity for time (6 minutes) and hCYP2D6 protein (0.0625 mg/ml). All
subsequent assays were carried out under the same conditions, irrespective of the
microsome source, with 5 mM N-desmethyltamoxifen (NDT) as substrate. For
AD inhibition assays, fluoxetine, amitriptyline, clomipramine, and imipramine
were coincubated with substrate. Paroxetine (at 2 concentration) was preincu-
bated with MLMs (0.125 mg/ml) and NADPH (1 mM) for 20 minutes before
addition of an equal volume of buffer containingNDT (10mM) and freshNADPH
(2 mM); therefore, concentrations of all components in the final reaction mixture
were the same for all ADs. Solvent (methanol) concentrations were 0.2% or lower
in all incubations.
In Vivo Studies. All animal work was carried out on 8- to 12-week-old female
mice. Paroxetine maleate salt was dissolved to 2.16 mg/ml in phosphate-buffered
saline to give a solution of 1.6 mg/kg paroxetine, which was administered at a
dose of 8 mg/kg orally (5 ml/g body weight). NDT was suspended in corn oil at
2 mg/ml for oral administration at 10 mg/kg (5 ml/g body weight). For sample
collection for pharmacokinetic (PK) analysis, 10 ml whole blood was withdrawn
from the tail vein at the indicated time points. Samples were immediately added to
a tube containing heparin solution (10 ml, 15 IU/ml) and stored at 220C until
processing.
Sample Processing for Liquid Chromatography–Tandem Mass Spec-
trometry. In vivo PK samples were thawed by the addition of 70 ml acetonitrile
containing the internal standard (tamoxifen-d5 at 0.2 mg/ml). After incubation on
ice for 10 minutes, in vivo and in vitro samples were vortexed (5 seconds) and
centrifuged for 10 minutes at 16,000g. The supernatant was added to 96-well
Fig. 1. Phase I metabolism of tamoxifen. P450s metabolize
tamoxifen through the “major” (N-demethylation followed
by 4-hydroxylation) or “minor” (4-hydroxylation followed
by N-demethylation) pathway, so denoted due to the relative
abundance of each metabolite in plasma samples (Stearns
et al., 2003; Madlensky et al., 2011). Conversion of NDT to
endoxifen is catalyzed exclusively by CYP2D6 (Desta et al.,
2004).
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plates for liquid chromatography (LC)–tandem mass spectrometry (MS/MS). As
with microsomal incubations, all samples were handled in amber tubes under
conditions of subdued light throughout the procedure.
LC-MS/MS. Analysis of in vitro incubation and in vivo blood PK samples was
carried out on a Waters Acquity ultra-performance LC system and a Micromass
Quattro Premier mass spectrometer (both Micromass, Manchester, UK). LC
separation was performed on a Kinetex 1.7mMC19 100A column (50 2.1 mm;
Phenomenex, Macclesfield, UK) at a temperature of 45C with an injection
volume of 5 ml and flow rate of 0.5 ml/min. Mobile phases were water containing
0.1% (v/v) formic acid (A) and acetonitrile containing 0.1% (v/v) formic acid (B).
Gradient elution was carried out from 70%/30% A/B to 30%/70% A/B over
2 minutes. Multiple reaction monitoring data in electrospray ionization–positive
mode were acquired for NDT [358.20 . 57.98; cone voltage (CV), 40 V; and
collision energy (CE), 25 kV], endoxifen [374.22 . 58.04; CV, 42 V; and CE,
23 kV], and tamoxifen-d5 [377.22. 71.87; CV, 45 V; and CE, 26 kV]. Acquired
data were analyzed in QuanLynx (Waters, Milford, MA) relative to analyte
standard curves spanning the range of concentrations under study. Analyte
recovery was high (approximately 90%) and the LC-MS/MS assay was highly
reproducible between runs, as reflected in the continuity of signal from the
calibration standards.
Data Analysis. In vitro kinetic data exhibited a substrate inhibition profile and
therefore were fitted with the following equation usingGraFit software (version 7;
Erithacus Software, Horley, UK): V = Vmax  [S]/[KS1 + [S]  (1 + [S]/KS2)],
where [S] is the substrate concentration, KS1 is the dissociation constant for
productive enzyme (substrate complex), and KS2 is the dissociation constant for
substrate bound to the inhibitory site. Spearman’s rank correlations and inhibition
parameters of ADs were calculated using GraphPad Prism software (version 6;
GraphPad Inc., La Jolla, CA). PK parameters of in vivo data were calculated with
a simple noncompartmental model using PK functions in Microsoft Excel
(Microsoft, Redmond,WA) and P values were calculated using an unpaired, one-
tailed t test.
Results
NDT Is Converted to Endoxifen by CYP2D6 in hCYP2D6
MLMs In Vitro. Under conditions of linearity for time and protein,
formation of endoxifen from NDT in hCYP2D6 liver microsomes
exhibited a kinetic profile suggestive of substrate inhibition (Fig. 2A).
Apparent kinetic parameters were obtained, with a KS1 of 5.16 0.4mM,
KS2 of 3.96 0.3 mM, and Vmax of 11286 57 pmol/min per mg. Under
the same incubation conditions, and with 5 mM NDT as substrate,
coincubation with 1 mM quinidine reduced endoxifen formation by
. 95% (Fig. 2B). Liver microsomes from Cyp2dKO mice did not
produce detectable levels of endoxifen, whereas liver microsomes from
wild-type mice produced 7.4-fold more endoxifen than hCYP2D6 liver
microsomes. In incubations with a high/low P450 activity HLM panel,
hydroxylation of NDT correlated most strongly with that of bufuralol,
the probe drug for CYP2D6, although a statistically significant
correlation was also observed with the probe for CYP2B6 (Table 1;
Supplemental Fig. 1).
ADs Inhibit the Conversion of NDT to Endoxifen by hCYP2D6
Liver Microsomes. To determine whether ADs could inhibit the
formation of endoxifen from NDT in hCYP2D6 liver microsomes,
two SSRIs (paroxetine and fluoxetine) and three tricyclic ADs
(amitriptyline, clomipramine, and imipramine) were individually titrated
into the optimized reactionmixture. Because paroxetine is a mechanism-
based inhibitor of CYP2D6 (Bertelsen et al., 2003), a 20-minute
preincubation step was carried out for this compound as described in
theMaterials and Methods. All compounds inhibited the reaction, with
Ki values (95% confidence intervals) of 57 nM (36.9–88.2 nM) for
paroxetine, 59 nM (39–89 nM) for fluoxetine, 720 nM (515–1008 nM)
for amitriptyline, 489 nM (351–680 nM) for clomipramine, and 838 nM
(576–1218 nM) for imipramine (Fig. 3).
Paroxetine Inhibits the CYP2D6-Mediated Conversion of NDT
to Endoxifen in hCYP2D6 Mice In Vivo. In patients receiving the
most common clinical dose of 20 mg tamoxifen per day, the average
blood plasma steady-state Cmax of NDT is approximately 200 ng/ml
(Lien et al., 2013; Jager et al., 2014). Preliminary studies in our
laboratory (data not shown) indicated that single doses of NDT required
to achieve similar concentrations were not well tolerated by all animals.
Hence, a dose of 10mg/kg NDTwas used here to give a reasonable level
of exposure, at approximately half of steady-state human levels, while
avoiding toxic effects. For paroxetine, although steady-state Cmax is not
dose proportional (Sindrup et al., 1992), it is approximately 150 ng/ml in
patients receiving the relatively high dose of 40 mg/d (http://www.gsk-
clinicalstudyregister.com/study/29060/474?study_ids=29060/474#rs).
We found that a single dose of 8 mg/kg paroxetine was appropriate to
achieve maximum plasma concentrations in hCYP2D6 mice that were
similar to this reported human value. Therefore, to establish whether the
in vitro interaction of NDT with paroxetine occurred in hCYP2D6 mice
in vivo, six animals were administered paroxetine and six were
administered phosphate-buffered saline vehicle alone, 1 hour prior to all
12 receiving NDT. Plasma levels of both of these compounds, and of
endoxifen, were monitored over the following 48-hour period. There
were no observed differences in the PK profile or apparent parameters of
Fig. 2. CYP2D6 converts NDT to endoxifen in hCYP2D6 mice. (A) Kinetic
analysis of endoxifen formation in hCYP2D6 MLMs (pooled from four animals).
Data represent combined means 6 S.D. of 10 technical replicates carried out on four
separate occasions. (B) Endoxifen formation in MLMs and HLMs. MLMs were
pooled from three (Cyp2dKO, WT) or four (hCYP2D6) individual animals. HLMs
were individual (13 donors) or pooled (150 donors). Data represent means 6 S.D. of
duplicate incubations and are representative of an experiment carried out on two
separate occasions. WT, wild type.
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NDT between groups (Fig. 4A). However, pretreatment with paroxetine
resulted in decreased exposure to endoxifen, with a highly significant
reduction in the area under the curve (AUCall) and a moderate but
nonsignificant decrease in Cmax (Fig. 4B; Table 2). Monitoring of
paroxetine levels in the pretreated group confirmed that the intended
level of exposure had been reached (Fig. 4C).
Discussion
Tamoxifen has been in clinical use for the treatment of cancer since the
1970s but the relatively recent discovery of endoxifen (Stearns et al., 2003),
coupled with an increased understanding of the phenotypic variability of
CYP2D6 (Zanger et al., 2004), has suggested opportunities for further
optimization of therapy. There is a general consensus that the interaction of
tamoxifen with CYP2D6 and strong inhibitors thereof may have some
bearing on the outcome of therapy, but prospective trials are needed to
determine the true extent of these effects, whether genotype-guided therapy
should be adopted, and whether coadministration of certain ADs with
tamoxifen should be avoided (Kelly et al., 2010; Province et al., 2014).
Reported steady-state concentrations of tamoxifen metabolites in
patient serum are highly variable but metabolism through NDT is
defined as the major route (with mean values of approximately 200, 10–
50, and 2–5 ng/ml for NDT, endoxifen, and 4-HT, respectively) (Fig. 1)
(Stearns et al., 2003; Madlensky et al., 2011; Lien et al., 2013;
Jager et al., 2014). However, in preliminary experiments with a single
15-mg/kg oral dose of tamoxifen in hCYP2D6 mice, we observed a 2.7-
fold higher value for blood concentrations of 4-HT than for NDT (Cmax
values for 4-HT and NDT were 235 and 86 ng/ml, respectively; data not
shown), indicating that the major and minor pathways were reversed in
this species. Hence, we deemed it necessary to bypass this conflict in
primary metabolism by using NDT as the substrate in our experiments.
Recently, this same problem has been encountered in a mouse model
containing humanizations for pregnane X receptor (PXR), constitutive
androstane receptor (CAR), CYP3A4/3A7, and CYP2D6 (hPXR/
hCAR/h3A4/3A7/2D6) (Chang et al., 2016). After administration of a
single dose of 20 mg/kg tamoxifen to this complex model, 4-HT levels
were found to be 5.4-fold higher than those of NDT (Cmax values for
4-HT and NDT were 248 and 46 ng/ml, respectively). As far as we are
aware, the mouse enzymes that mediate this preferential hydroxylation
of tamoxifen are yet to be identified.
There are over 100 identified allelic variants of CYP2D6 (http://
www.cypalleles.ki.se/cyp2d6.htm), with varying levels of activity
in the metabolism of compounds of both endogenous and exogenous
origin (Yu et al., 2004; Zanger et al., 2004). Depending on patients’
CYP2D6 status, they may be classed as poor, intermediate, extensive, or
ultrarapid metabolizers (Cascorbi, 2003; De Gregori et al., 2010). This
phenotypic status can be determined through the analysis of the
urinary ratio of debrisoquine to its CYP2D6-generated metabolite,
4-hydroxydebrisoquine (Dalén et al., 1999). In a previous study, we
found that wild-type mice and Cyp2dKO mice were representative of
human poor metabolizers in this regard, whereas hCYP2D6 mice were
representative of extensive metabolizers (Scheer et al., 2012). In this
study, we show that, in vitro, liver microsomes from Cyp2dKOmice are
incapable of generating endoxifen fromNDT, whereas wild-typeMLMs
do so at a rate that greatly exceeds that of HLMs. This comparatively
high activity ofmurine P450s has been seen for other drugs andmaybe due,
at least in part, to the multiplicity of these enzymes (Hrycay and Bandiera,
2009; Hasegawa et al., 2011; Scheer et al., 2012). Humanization for
CYP2D6 both removes this high-activity murine component and incorpo-
rates the functional human component, rendering the amount of endoxifen
produced more in line with that of the members of the HLM panel that
possess the highest level of activity toward theCYP2D6 probe (bufuralol).
As with the urinary ratio of debrisoquine to 4-hydroxydebrisoquine,
therefore, it appears that Cyp2dKO and hCYP2D6 mice are at either
end of the CYP2D6 phenotypic spectrum in relation to NDT metab-
olism in vitro. Our data for hCYP2D6 MLMs yielded a KS1 value of
5.1 6 0.4 mM, which is consistent with the Km values of 4.5 and 5.9
mM reported by Desta et al. (2004) in their analyses of two individual
HLM preparations. These authors also noted that, in a third HLM
preparation, endoxifen was formed at a very slow rate. Our observations
are also consistent with those of Chang et al. (2016), who reported a Km
value of 5.9 mM for 4-HT hydroxylation in their recent work with liver
TABLE 1
Spearman’s rank correlation of conversion of NDT to endoxifen with P450 probe substrate metabolism in a panel
of 13 HLMs
Spearman’s rank correlation coefficient of NDT hydroxylation with metabolism of P450 probe substrates is shown. Probe substrate
values were provided by the vendor.
Enzyme Probe Substrate Activity SRCC with NDT Hydroxylation P Value
1A2 Phenacetin O-deethylation 20.289 0.360
2A6 Coumarin 7-hydroxylation 0.161 0.600
2B6 S-mephenytoin N-demethylation 0.572 0.045
2C8 Paclitaxel 6a-hydroxylation 0.380 0.186
2C9 Diclofenac 49-hydroxylation 0.526 0.076
2C19 S-mephenytoin 49-hydroxylation 20.220 0.444
2D6 Bufuralol 19-hydroxylation 0.698 0.010
2E1 Chlorzoxazone 6-hydroxylation 0.311 0.281
3A4 Testosterone 6b-hydroxylation 20.005 0.993
4A11 Lauric acid 12-hydroxylation 20.290 0.316
SRCC, Spearman’s rank correlation coefficient.
Fig. 3. Conversion of NDT to endoxifen in hCYP2D6 MLMs is inhibited by ADs.
Paroxetine was preincubated with MLMs before addition of NDT, as described in
the Materials and Methods. All other compounds were coincubated with NDT. Data
represent means of duplicate incubations and are representative of an experiment
carried out on two separate occasions.
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microsomes from the hPXR/hCAR/h3A4/3A7/2D6 model. Furthermore,
we found that NDT hydroxylation correlated most strongly with bufuralol
hydroxylation in a panel of HLMs, confirming the wider importance of
CYP2D6 in this context. We also observed, however, a correlation with
S-mephenytoinN-demethylation, the probe activity for CYP2B6.Although
this correlation barely achieved statistical significance, this raises the
possibility that there may be a role for this enzyme in the generation of
endoxifen from NDT, which deserves further investigation.
Here, the SSRIs paroxetine and fluoxetine inhibited the CYP2D6-
dependent formation of endoxifen in hCYP2D6 MLM incubations,
with Ki values of 57 nM and 59 nM, respectively. These values are
somewhat lower than the 360 nM (paroxetine) and 240 nM (fluox-
etine) previously reported by Bertelsen et al. (2003) in the inhibition
of dextromethorphan O-demethylation by HLMs but, in the case of
paroxetine, other reported values are closer to our observed value
(Crewe et al., 1992; Fogelman et al., 1999). Tricyclic ADs were an
order of magnitude less effective in inhibiting NDT hydroxylation.
Paroxetine is a strong inhibitor of CYP2D6 (http://www.fda.gov/
Drugs/DevelopmentApprovalProcess/DevelopmentResources/
DrugInteractionsLabeling/ucm093664.htm#cypEnzymes) and is the
most likely AD to exert a negative influence on the outcome of
tamoxifen therapy (Borges et al., 2006; Kelly et al., 2010). Here, we
observed a substantial decrease in exposure (AUCall) to endoxifen in
hCYP2D6mice treated with NDT and paroxetine, relative to the control,
demonstrating that this drug–drug interaction occurs in vivo. Crucially,
the maximum plasma concentrations of NDT and paroxetine were
similar to those evident in patients at steady state (Lien et al., 2013; Jager
et al., 2014; http://www.gsk-clinicalstudyregister.com/study/29060/
474?study_ids=29060/474#rs). We did not observe the converse effect
with NDT (i.e., an increased exposure in the presence of paroxetine).
This finding suggests that the routes of elimination for NDT and
endoxifen may be different and is in agreement with data from the
hPXR/hCAR/h3A4/3A7/2D6 model (Chang et al., 2016). Indeed, 4-OH
metabolites of tamoxifen, including endoxifen, are known to be
glucuronidated and sulfated (Poon et al., 1993; Kisanga et al., 2005). It
would therefore be informative to determine, in future experiments,
whether the profiles of these and other circulating and excreted
conjugates are altered with paroxetine coadministration. Furthermore,
it would be interesting to ascertain whether paroxetine has a more
profound effect on endoxifen levels in hCYP2D6mice at steady state. As
discussed above, hCYP2D6 mice align with the CYP2D6 extensive-
metabolizer phenotype, yet we saw decreases of only 21% in Cmax and
only 28% in AUCall. Although this has to be viewed in consideration of
the rapid elimination of paroxetine in our study, these values may be
more in line with the 64%–71% decrease seen in patients at steady-state
levels of both NDT and paroxetine (Stearns et al., 2003; Borges et al.,
2006). Although plasma levels of paroxetine in hCYP2D6 mice were an
order of magnitude higher than the observed in vitro Ki for inhibition of
NDT hydroxylation (670 nM versus 57 nM), significant quantities of
endoxifen were still produced. One possible explanation for this is the
high level of binding of paroxetine with murine plasma proteins, which
(at .96%) is similar to the reported human value, because inhibition of
CYP2D6 may be dependent on the free drug concentration (van Harten,
1993; Qin et al., 2016). Consistent with the in vitro analyses that
indicated that hCYP2D6 liver microsomes were at least 2.6-fold more
efficient than any member of the HLM panel in generating endoxifen, it
should be noted that endoxifen levels were higher (between 2.5- and
13-fold) than in human subjects (Jin et al., 2005; Lien et al., 2013; Jager
et al., 2014).
In the in vivo study presented here, we attempted to incorporate a
pharmacodynamic endpoint by Western blotting for ER targets (Cdc2,
Mad2, and p21) in the endometrium, where tamoxifen is known to exert
proestrogenic effects, but no changes were observed (data not shown).
This may be because of the short-term nature of the study: chronic
administration of tamoxifen/NDT may be required to generate the
precancerous changes observed in human patients. We also investigated
the utility of the C57BL/6-derived E0771 cell line for potential
syngeneic tumor studies. As observed by Gu et al. (2009), this cell line
expresses ERa at a level far lower than in the estrogen-dependent MCF7
human cell line. Indeed, we found that E0771 cells exhibited no
Fig. 4. Paroxetine inhibits conversion of NDT (A) to endoxifen (B) in hCYP2D6
in vivo. (C) Animals were dosed with paroxetine (8 mg/kg, n = 6) or vehicle (n = 6)
and then, 1 hour subsequently, all were dosed with NDT (10 mg/kg). Data shown are
means 6 S.E.M.
TABLE 2
PK parameters of endoxifen in hCYP2D6 mice
Parameters (means 6 S.D.) are shown for vehicle (n = 6) and paroxetine (n = 6) pretreated
groups.
Group t1/2 Cmax AUCall
h ng/ml h×ng/ml
Vehicle 14.3 6 4.7 132 6 46 3508 6 797
Paroxetine 13.8 6 3.1 104 6 12 2525 6 321*
P value 0.416 0.094 0.009
t1/2, half-life. *P ,0.05.
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dependence whatsoever on estradiol for their growth in vitro (Supple-
mental Fig. 2). Future work incorporating pharmacodynamic endpoints,
such as the antitumor activity of NDT in xenografted immunodeficient
hCYP2D6 and Cyp2dKO mice, would allow the further evaluation of
tamoxifen interactions with CYP2D6 phenotype and ADs.
In summary, we have shown that humanization for CYP2D6 is
both necessary and sufficient to render the mouse human-like in its
disposition to NDT. In modeling human-specific aspects of tamoxifen
metabolism in vivo, we have demonstrated that ADs, particularly those
of the SSRI class, have the capacity to alter systemic exposure to
pharmacologically potent metabolites, which may influence therapeutic
outcome. Our work exemplifies the utility of humanized mouse models
for the nonclinical study of drug metabolism.
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